Skip to main content
. Author manuscript; available in PMC: 2024 Aug 24.
Published in final edited form as: ACS Infect Dis. 2021 Jul 14;7(8):2522–2535. doi: 10.1021/acsinfecdis.1c00270

Figure 2.

Figure 2.

AHAS and NLRP3 Binding Sites. (A) MCC950 and key binding residues in proposed NLRP3 binding site. (B) 2D ligand interaction diagram of MCC950 in NLRP3 binding site. (C) Sulfometuron methyl and key binding residues in Sc-AHAS active site. FAD cofactor visible in background. (D) 2D ligand interaction diagram of sulfometuron methyl in AHAS active site.